Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade) [Seeking Alpha]
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Gross margin improved to 85%, yet investors reacted to slowing Recorlev growth and rising costs from Recorlev expansion and XP-8121 clinical trials. I downgrade XERS to a Hold, recommending gradual accumulation on weakness, as upside potential remains. Tom Werner/DigitalVision via Getty Images Thesis In my previous article , I rated Xeris Biopharma Holdings, Inc. ( XERS ) as a 'Buy' because the company's revenue was accelerating thanks to Recorlev, and the XP-8121 pipeline presented significant upside potential. While I still believe This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of CORT, XERS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past perform
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
- Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- What Analysts Think Is Changing The Story For Xeris Biopharma Holdings [Yahoo! Finance]Yahoo! Finance
- Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent ApplicationBusiness Wire
XERS
Earnings
- 11/6/25 - Miss
XERS
Sec Filings
- 12/15/25 - Form 4
- 12/12/25 - Form 144
- 12/2/25 - Form 4
- XERS's page on the SEC website